Fosravuconazole

DB15204InvestigationalSmall molecule

Fosravuconazole is under investigation in clinical trial NCT03378661 (BENDITA BEnznidazole New Doses Improved Treatment and Associations).

Mechanism: Pharmacologically active on Lanosterol 14-alpha demethylase
Curator reviewed
Formula / weight: C₂₃H₂₀F₂N₅O₅PS · 547.47 g/mol (avg)

Resolves to

Compound

Clinical / RWD

Structure

InChIKeySYTNEMZCCLUTNX-NPMXOYFQSA-NSMILESC[C@@H](C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@@](CN1C=NC=N1)(OCOP(O)(O)=O)C1=CC=C(F)C=C1F

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 3 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fosravuconazole, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.